Уважаемые пользователи!

Данный сайт содержит информацию для людей с медицинским образованием и специалистов здравоохранения.
Входя на сайт, Вы подтверждаете свое согласие с Условиями использования и Политикой конфиденциальности.



Dear visitor!
This site contains medical information for healthcare professionals.
You can go further, if you agree with Terms and Conditions and Privacy Policy on this site.

Rol' sinteticheskogo liganda PPARy-rosiglitazona v patogeneticheskom lechenii sakharnogo diabeta 2 tipa

Cover Page

Abstract


Росиглитазон (Авандия) обеспечивает значительное снижение глюкозы плазмы натощак, HbAlc
и уровня постпрандиальной гликемии. Достигнутая компенсация углеводного обмена сохраняется длительное время. Росиглитазон эффективен в качестве монотерапии и в комбинации с метформином, производными сульфонилмочевины и с инсулином, как при однократном, так и при двукратном приеме вне зависимости от приема пищи. Росиглитазон эффективен как у больных СД 2
типа, имеющих ожирение, так и без ожирения. Росиглитазон улучшает функцию бета-клеток и
тем самым способен замедлять прогрессирование заболевания. Воздействуя практически на все компоненты метаболического синдрома, росиглитазон способен снижать риск развития и прогрессирования сердечно-сосудистых заболеваний.

Irina Vladimirovna Kononenko

Endocrinology Research Centre, Moscow

Olga Mikhailovna Smirnova

Endocrinology Research Centre, Moscow

  1. Albert М.А., Ridker P.M. The role of C-reactive protein in cardiovascular disease risk.//Current Cardiology Reports. - 1999. - V. 1. - P. 99-104.
  2. Beales P., Liddi R., Giorgini A. et al. Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse. / / Eur J Pharmacol. - 1998. - Vol. 357. - P. 221 - 225.
  3. Beales P., Rosignoli G., Liddi R. et al. Rosiglitazone reduces diabetes incidence in the NOD mouse. / / Diabetes Res Clin Pract. - 2000. -Vol. 50 (Suppl. 1).-P. 1518.
  4. Brunzell J., Cohen B.R., Kreider M. et al. Rosiglitazone favorably affects LDL-C and HDL-C heterogeneity in type 2 diabetes.// Diabetes. - 2001. - V . 50 (Supplement 2). A l 4 1 .
  5. Beebe K.L., Patel J. Rosiglitazone is effective and well tolerated in patients > 65 years with type 2 diabetes.// Diabetes. - 1999. - V.48 (Supplement 1). A l 1 1.
  6. Banerji M., Lebovitz H.E., Dugbartey M. Rosiglitazone selectively increases subcutaneous but not visceral adipose tissue mass in type 2 diabetes mellitus.// Diabetes. - 2001. - V.50 (Supplement 2). А90
  7. Charbonnel В., Lonnqvist F., Jones N.P. et al. Rosiglitazone is superior to glyburide in reducing fasting plasma glucose after 1 year of treatment in type 2 diabetic patients.// Diabetes. - 1999. - V. 48 (Supplement 1). АП4-А115.
  8. Clifford J Bailey, Caroline Day. Thiazolidinediones today. / / Br J of Diabetes Vase Dis. - 2001. - Vol. 1 Is. 1. - H.7-13.
  9. Cranmer H., Jones N.P., Patwardhan R. Rosiglitazone is effective in both obese and non-obese patients with type 2 diabetes.// Diabetologia. - 1999. - V. 42 (Supplement 1). A228.
  10. DeFronzo R.A.:Pathogenesis of Type 2 (non-insulin-dependent) diabetes mellitus: a balanced overview. Diabetologia - 1992; - 35; - P.389 - 397.
  11. DeFronzo R.A. Lilly Lecture. The triumvirate: beta cell, muscle, liver. A collusion responsible for NIDDM. / / Diabetes. - 1988. - Vol. 37. - P. 667-687.
  12. DeFronzo R.A, Gunnarsson R, Bjorkman O, Olsson M. Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulin dependent diabetes mellitus. / / J Clin Invest. - 1985.-Vol.76. - P. 149-155.
  13. Fonseca V.A., Biswas N., Salzman A. Once-daily rosiglitazone (RSG) in combination with metformin (MET) effectively reduces hyperglycemia in patients with type 2 diabetes.// Diabetes. 1999. V. 48 (Supplement 1). A l 00.
  14. Freed M., Fuell D., Menci L. et al. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity and tPA in patients with type 2 diabetes.// Diabetologia. - 2000. - V. 43 (Supplement 1). A267.
  15. Grunberger G., Weston W.M., Patwardhan R. et al. Rosiglitazone once or twice daily improves glycemic control in patients with type 2 diabetes.// Diabetes. - 1999. - V . 48 (Supplement 1). A102.
  16. GlaxoSmithKline. Data on file. 2001.
  17. Gomis R., Jones N.P., Vallance S.E. et al. Low-dose rosiglitazone provides additional glycemic control when combined with sulfonylureas in type 2 diabetes (T2D). / / Diabetes. - 1999. - V. 48 (Supplement 1). A63.
  18. 8. Greenberg A., Haffner S., Weston W. et al. Rosiglitazone reduces Creactive protein, a marker of systemic inflammation in type 2 diabetic patients.// Diabetologia. - 2001. - V. 44 (Supplement 1). A222.
  19. Haring H.U.:Molecular biology of insulin action and resistance. In: E. Standi (Ed.): Perspectives of the hyperinsulinaemia/insulin resistance syndrome in NIDDM: From pathophysiology to clinical implications. MMV Medizin Verlag, Munchen -1 990. - V.9 - P.20.
  20. Hennes M.M., Shrago E., Kissebah A.: Receptor and postreceptor effects of free fatty acids (FFA) on hepatocyte insulin dynamics. Int. J. Obesity - V.I 4 - 1990-P.831 - 41
  21. Hsueh WA, Law RE. Arterioscler Thromb Vase Biol. 2001 ;21:1 891 -1895
  22. Insulin Resistance. Editer by Gerald M.Reaven.1999. Humana Press. Chapter 9. 170-173.
  23. Kim Y.-B., Ciaraldi T.P., Kong A. et al. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p i 10b protein levels in skeletal muscle of type 2 diabetic subjects. //Diabetes. - Feb 2002. - V. 5 1 .
  24. Kreider M., Miller E., Patel J. Rosiglitazone is safe and well tolerated as monotherapy or cimbination therapy in patients with type 2 diabetes mellitus (T2DM).// Diabetes. - 1999. - V. 48 (Supplement 1). A l 17.
  25. Lebovitz H.E., Dole J.F., Patwardhan R. et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. / / J Clin Endocrinol Metab. - 2 0 0 1 . - V . 86.-P.280-288.
  26. Miyazaki Y et al. J Clin Endocrinol Metab. - 2002 - V.87 - P.2784-2791
  27. Miyazaki Y., Matsuda M., Mahankali A. et al. Mechanisms of glucoselowering effect by rosiglitazone in patients with type 2 diabetes.// Diabetes - 2001 - V. 50 (Supplement 2). A126.
  28. Miyazaki Y., Mahankali A., Matsuda M. et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.//Diabetes Care - 2001 - V. 24(4) - P. 710-719.
  29. Marceille J.R., Goins A.J., Soni R. et al. Chronic heart failure - related interventions after starting rosiglitazone in patients receiving insulin.// Pharmacotherapy - 2004 - V.24( 10) - P. 1317-1322.
  30. Oakes N.D., Kennedy C.J., Jenkins A.B. et al. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. / / Diabetes. - 1994. - V. 43. - P. 1203-1210. 35. 36. 37.
  31. Park K.-S., Ciaraldi T.P., Abrams-Carter L. et al. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects. / / J Clin Endocinol Metab. - 1998. - V. 83. - P.l 636-1643.
  32. Philips L.S., Grunberger G., Miller E. et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in with type 2 diabetes. //Diabetes Care. - 2001. - V. 24. - P.308-315.
  33. Page R.L. II, Gozansky W.S., Ruscin J.M. Possible heart failure exacerbation associated with rosiglitazone and literature review. / / Pharmacotherapy. - 2003. - V. 23(7). - P. 945-954.
  34. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus / / Diabetes Care. - 1997. - Vol.20. - P. 219-220
  35. Reaven G.M. The fourth Musketeer - from Alexandre Dumas to Claude Bernard. / / Diabetologia. - 1995. - Vol. 38. - P. 3 - 13.
  36. Reaven G.M.: Banting Lecture 1 988: role of insulin resistance in human disease. Diabetes 1988; 37; 1595-1607.
  37. Rosen E.D., Spiegelman B.M. Molecular regulation of adipogenesis. / / Ann. Rev. Dev. Biol. - 2000. - V. 16. - P. 145-171.
  38. Ross R. Atherosclerosis - an inflammatory disease. / / New England Journal of Medicine. - 1999. - V. 340. - P. 115-126.
  39. Rachman J., Payne M.J., Levy J.C. et al. Changes in amylin and amylinlike peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.//Diabetes Care. - 1 998. - V.21. - P.810-816.
  40. Raskin P., Dole J.F., Rappaport E.B. Rosiglitazone improves glycemic control in poorly controlled, insulin-treated type 2 diabetes (T2D). / / Diabetes. - 1999. - V. 48 (Supplement 1). A94.
  41. Shulman G.I., Rothman D.L., Jue T. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med. - 1990. - V.322 - P.223-228.
  42. SmithKline Beecham. Avandia prescribing information. 2001.
  43. Spiegelman B.M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.//Diabetes. - 1998. - V.47. - P. 507-514.
  44. Stewart M., Jones N.P., Kreider M. et al. Combined effects of rosiglitazone and atorvastatin on the dyslipidemia associated with type 2 diabetes.// Diabetologia. 2001. V. 44 (Supplement 1). A222.
  45. Salzman A., Patel J. Rosiglitazone therapy is not associated with hepatotoxicity.// Diabetes. 1999. V. 48 (Supplement 1). A95.
  46. Unger R.H. Lipotoxity in the pathogensis of obesity-dependent NIDDM. Genetic and clinical implications. / / Diabetes. - 1995. - Vol. 44. - P. 863-870.
  47. Uemura S., Matsushita H., Li W. et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. / / Circulation Research. - 2001. - V.88. - P. 1291-1298.
  48. UK Prospective Diabetes Study (UKPDS) Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. / / Diabetes. - 1995. - V.44. - P. 1249-1258.
  49. Vongthavaravat V, Bernardo L.W., Jorge N.W. et al. An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes. / / Curr Med Res Opin. - 2002. - V. 18(8). - P. 456-461.
  50. Werner A.L., Travaglini M.T. A review of rosiglitazone in type 2 diabetes mellitus. / / Pharmacotherapy. - 2001. - V. 21(9). - P. 1082-1099.
  51. Yoshinori Miyazaki, Helen He. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. / / Diabetes. - 2003. - Vol. 52 (8). - P. 1943-1950.
  52. Yoshimoto T et al. Atherosclerosis. - 1999. - V. 145 - P.333-340.
  53. Young P.W., Buckle D.R., Cantello B.C. et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BPL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferators-activated receptor gamma.//Journal of Pharmacology and Experimental Therapeutics. - 1998. - V. 284. - P. 751-759.
  54. Young P.W., Cawthorne M.A., Coyle P.J. et al. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. / / Diabetes. - 1995. -V.44. - P.1087-1092.

Views

Abstract - 650

PDF (Russian) - 229

Cited-By


PlumX


Copyright (c) 2005 Kononenko I.V., Smirnova O.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.